



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

FEB 19 2003

TECH CENTER 1600/2900

Application of: **Yu, et al.**

Application Number: 09/589,288

Group Art Unit: 1646

Filed: June 8, 2000

Examiner: Bunner, B.

Title: **Methods of Treatment Using Antibodies** Atty. Docket No. PF343P3C5
to Neutrokin-alpha (as amended)

AMENDMENT AND RESPONSE UNDER 37 C.F.R. §1.116

BOX AF

Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Official Action dated August 13, 2002 (Paper No. 13), Applicants request that the following amendments and remarks be entered into the above-identified application. Applicants submit concurrently herewith:

- (a) Version with Markings to Show Changes Made;
- (b) Exhibit A: Huard et al., T cell costimulation by the TNF Ligand BAFF, *The Journal of Immunology*, (2001) 167:6225-6331;
- (c) Exhibit B: Kayagaki et al., BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-kappaB2. *Immunity* (2002) 10:515-24;
- (d) Exhibit C: Janeway, C. & P. Travers. *Immunobiology: The Immune System in Health and Disease*, (Current Biology Ltd./Garland Publishing, London) 1994. pp. 11:14 and G:1;
- (e) Exhibit D: Abbas et al., *Cellular and Molecular Immunology* (W.B. Saunders Company: Philadelphia) 1991. p. 370;
- (f) A Notice of Appeal;
- (g) Petition For Extension of Time Under 37 C.F.R. § 1.136(a); and
- (h) Fee Transmittal Sheet.

15/D
A.9-J
2/20/03
(NE)

OK to enter
Feb 5/14/03